Home Other Building Blocks 168021-79-2
168021-79-2,MFCD09833648
Catalog No.:AA001XOF

168021-79-2 | Cerovive

Pack Size
Purity
Availability
Price(USD)
Quantity
  
5mg
≥98%
in stock  
$69.00   $48.00
- +
10mg
≥98%
in stock  
$128.00   $89.00
- +
25mg
≥98%
in stock  
$252.00   $176.00
- +
50mg
≥98%
in stock  
$463.00   $324.00
- +
250mg
≥99%
in stock  
$2,156.00   $1,509.00
- +
500mg
98% by HPLC
in stock  
$2,920.00   $2,044.00
- +
1000mg
98% by HPLC
in stock  
$4,634.00   $3,244.00
- +
  • Technical Information
  • Properties
  • Literature
  • Request for Quotation
  • Download SDS
  • Technical Information
  • Properties
  • Literature
Technical Information
Catalog Number:
AA001XOF
Chemical Name:
Cerovive
CAS Number:
168021-79-2
Molecular Formula:
C11H13NNa2O7S2
Molecular Weight:
381.3330
MDL Number:
MFCD09833648
SMILES:
[O-]/[N+](=C\c1ccc(cc1S(=O)(=O)[O-])S(=O)(=O)[O-])/C(C)(C)C.[Na+].[Na+]
Properties
Computed Properties
 
Complexity:
578  
Covalently-Bonded Unit Count:
3  
Defined Bond Stereocenter Count:
1  
Heavy Atom Count:
23  
Hydrogen Bond Acceptor Count:
7  
Rotatable Bond Count:
2  

Literature

Title: To serve and neuroprotect.

Journal: Nature medicine 20120706

Title: Neuroprotection for ischaemic stroke: translation from the bench to the bedside.

Journal: International journal of stroke : official journal of the International Stroke Society 20120701

Title: Potential implication of the chemical properties and bioactivity of nitrone spin traps for therapeutics.

Journal: Future medicinal chemistry 20120601

Title: Neuroprotection for stroke: current status and future perspectives.

Journal: International journal of molecular sciences 20120101

Title: Anti-adrenergic medications and edema development after intracerebral hemorrhage.

Journal: Neurocritical care 20110601

Title: Emulating multicentre clinical stroke trials: a new paradigm for studying novel interventions in experimental models of stroke.

Journal: International journal of stroke : official journal of the International Stroke Society 20091201

Title: Cerebrovascular protection as a possible mechanism for the protective effects of NXY-059 in preclinical models: an in vitro study.

Journal: Brain research 20091019

Title: Effects of NXY-059 in experimental stroke: an individual animal meta-analysis.

Journal: British journal of pharmacology 20090801

Title: Stroke research at a road block: the streets from adversity should be paved with meta-analysis and good laboratory practice.

Journal: British journal of pharmacology 20090801

Title: Scope of preclinical testing versus quality control within experiments.

Journal: Stroke 20090701

Title: Serendipitous findings while researching oxygen free radicals.

Journal: Free radical biology & medicine 20090415

Title: Cosmic implications of NXY-059.

Journal: Stroke 20090301

Title: Methodological quality of animal studies of neuroprotective agents currently in phase II/III acute ischemic stroke trials.

Journal: Stroke 20090201

Title: The nitrone free radical scavenger NXY-059 is neuroprotective when administered after traumatic brain injury in the rat.

Journal: Journal of neurotrauma 20081201

Title: Pharmacokinetics of 8-hour intravenous infusion of NXY-059: a phase I, randomized, double-blind (within dose panels), placebo-controlled study in healthy Chinese volunteers.

Journal: Clinical therapeutics 20081201

Title: Evidence for the efficacy of NXY-059 in experimental focal cerebral ischaemia is confounded by study quality.

Journal: Stroke 20081001

Title: NXY-059 for the treatment of acute stroke: pooled analysis of the SAINT I and II Trials.

Journal: Stroke 20080601

Title: Antithrombotic and thrombolytic therapy for ischemic stroke.

Journal: Cardiology clinics 20080501

Title: A Critique of SAINT II: wishful thinking, dashed hopes, and the future of neuroprotection for acute stroke.

Journal: Stroke 20080401

Title: [Development of new stroke therapies: outlook for neuroprotective drugs].

Journal: Der Nervenarzt 20080201

Title: Neuroprotection in cerebral ischemia: emphasis on the SAINT trial.

Journal: Current cardiology reports 20080201

Title: The nitrone disodium 2,4-sulphophenyl-N-tert-butylnitrone is without cytoprotective effect on sodium nitroprusside-induced cell death in N1E-115 neuroblastoma cells in vitro.

Journal: Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 20080101

Title: Missing steps in the STAIR case: a Translational Medicine perspective on the development of NXY-059 for treatment of acute ischemic stroke.

Journal: Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 20080101

Title: The use of the Chandler loop to examine the interaction potential of NXY-059 on the thrombolytic properties of rtPA on human thrombi in vitro.

Journal: British journal of pharmacology 20080101

Title: Comments regarding the recent OAST article.

Journal: Stroke 20080101

Title: The 2007 Feinberg lecture: a new road map for neuroprotection.

Journal: Stroke 20080101

Title: A novel inhibitor of advanced glycation and endoplasmic reticulum stress reduces infarct volume in rat focal cerebral ischemia.

Journal: Brain research 20071205

Title: Neuroprotection in the SAINT-II aftermath.

Journal: Annals of neurology 20071201

Title: NXY-059 for the treatment of stroke.

Journal: The New England journal of medicine 20071122

Title: Life after SAINT.

Journal: International journal of stroke : official journal of the International Stroke Society 20071101

Title: SAINT-I worked, but the neuroprotectant is not NXY-059.

Journal: Stroke 20071001

Title: Investigating the free radical trapping ability of NXY-059, S-PBN and PBN.

Journal: Free radical research 20070901

Title: Advances in hemorrhagic stroke therapy: conventional and novel approaches.

Journal: Expert opinion on emerging drugs 20070901

Title: NXY-059 for the treatment of acute ischemic stroke.

Journal: The New England journal of medicine 20070809

Title: Safety and tolerability of NXY-059 for acute intracerebral hemorrhage: the CHANT Trial.

Journal: Stroke 20070801

Title: A phase 1, placebo-controlled, randomised, double-blind (within dose panels) study evaluating the safety, tolerability and pharmacokinetics of intravenous NXY-059 in Japanese subjects.

Journal: Current medical research and opinion 20070801

Title: A study of organic acid transporter mediated pharmacokinetic interaction between NXY-059 and cefuroxime.

Journal: Journal of clinical pharmacology 20070801

Title: Effect of NXY-059, a novel neuroprotectant, on the pharmacokinetics of a single dose of digoxin in healthy subjects.

Journal: Current medical research and opinion 20070701

Title: Active renal secretion of NXY-059, a novel neuroprotectant, is mediated via an organic acid transporter.

Journal: Journal of clinical pharmacology 20070701

Title: Life after cerovive: a personal perspective on ischemic neuroprotection in the post-NXY-059 era.

Journal: Stroke 20070601

Title: Clinical impact of NXY-059 demonstrated in the SAINT I trial: derivation of number needed to treat for benefit over entire range of functional disability.

Journal: Stroke 20070501

Title: A critical appraisal of the NXY-059 neuroprotection studies for acute stroke: a need for more rigorous testing of neuroprotective agents in animal models of stroke.

Journal: Experimental neurology 20070501

Title: NXY-059 does not affect bleeding time in healthy volunteers: a randomized, double-blind, placebo-controlled, 3-period crossover phase I study.

Journal: Journal of clinical pharmacology 20070201

Title: Stroke: the dashed hopes of neuroprotection.

Journal: The Lancet. Neurology 20070101

Title: Neuroprotective effects of free radical scavengers in stroke.

Journal: Drugs & aging 20070101

Title: Additional outcomes and subgroup analyses of NXY-059 for acute ischemic stroke in the SAINT I trial.

Journal: Stroke 20061201

Title: Translational vehicles for neuroprotection.

Journal: Biochemical Society transactions 20061201

Title: NXY-059 does not significantly interact with furosemide in healthy volunteers.

Journal: Journal of clinical pharmacology 20061201

Title: Hypokalemia, cardiac failure, and reporting NXY-059 safety for acute stroke.

Journal: Journal of cardiovascular pharmacology and therapeutics 20061201

Title: The bitterest pill.

Journal: Nature 20061130

Title: Novel therapies for acute ischemic stroke.

Journal: The Israel Medical Association journal : IMAJ 20061101

Title: NXY-059 for acute ischemic stroke: the promise of neuroprotection is finally realized?

Journal: Stroke 20061001

Title: On the analysis and interpretation of outcome measures in stroke clinical trials: lessons from the SAINT I study of NXY-059 for acute ischemic stroke.

Journal: Stroke 20061001

Title: NXY-059: a hopeful sign in the treatment of stroke.

Journal: Stroke 20061001

Title: Safety, tolerability and pharmacokinetics of escalating doses of NXY-059 in healthy young and elderly subjects.

Journal: Current medical research and opinion 20060901

Title: NXY-059: brain or vessel protection.

Journal: Stroke 20060801

Title: Therapeutic strategies for the treatment of stroke.

Journal: Drug discovery today 20060801

Title: Neuroprotection and thrombolysis: combination therapy in acute ischaemic stroke.

Journal: Expert opinion on pharmacotherapy 20060801

Title: NXY-059 for acute ischemic stroke.

Journal: The New England journal of medicine 20060511

Title: NXY-059 for acute ischemic stroke.

Journal: The New England journal of medicine 20060511

Title: Is NXY-059 an advancement in the treatment of acute ischaemic stroke?

Journal: Expert opinion on pharmacotherapy 20060501

Title: Researchers focus on improving treatments for acute ischemic stroke.

Journal: JAMA 20060412

Title: Neuroprotection for acute ischaemic stroke: hope reignited.

Journal: The Lancet. Neurology 20060401

Title: Stroke - international conference 2006.

Journal: IDrugs : the investigational drugs journal 20060401

Title: NXY-059: review of neuroprotective potential for acute stroke.

Journal: The Annals of pharmacotherapy 20060301

Title: Brain penetration of the novel free radical trapping neuroprotectant NXY-059 in rats subjected to permanent focal ischemia.

Journal: Brain research 20060209

Title: Stroke and neurovascular protection.

Journal: The New England journal of medicine 20060209

Title: NXY-059 for acute ischemic stroke.

Journal: The New England journal of medicine 20060209

Title: The ischemic penumbra: a new opportunity for neuroprotection.

Journal: Cerebrovascular diseases (Basel, Switzerland) 20060101

Title: Other neuroprotective therapies on trial in acute stroke.

Journal: Cerebrovascular diseases (Basel, Switzerland) 20060101

Title: Reducing the burden of stroke.

Journal: Lancet (London, England) 20051119

Title: [Follow up of a contribution about treatment of acute apoplexy].

Journal: Ugeskrift for laeger 20050808

Title: Widening the window. Strategies to buy time in treating ischemic stroke.

Journal: Scientific American 20050801

Title: Nitrone derivatives of trolox as neuroprotective agents.

Journal: Bioorganic & medicinal chemistry letters 20050615

Title: Free radical trapping as a therapeutic approach to neuroprotection in stroke: experimental and clinical studies with NXY-059 and free radical scavengers.

Journal: Current drug targets. CNS and neurological disorders 20050401

Title: Population pharmacokinetic modelling and estimation of dosing strategy for NXY-059, a nitrone being developed for stroke.

Journal: Clinical pharmacokinetics 20050101

Title: NXY-059: a neuroprotective agent in acute stroke.

Journal: International journal of clinical practice 20041001

Title: Extending the window for acute stroke treatment: thrombolytics plus CNS protective therapies.

Journal: Experimental neurology 20040801

Title: Coadministration of NXY-059 and tenecteplase six hours following embolic strokes in rabbits improves clinical rating scores.

Journal: Experimental neurology 20040801

Title: Oxygen free radical traps for the treatment of ischemia-associated organ injury.

Journal: Current opinion in investigational drugs (London, England : 2000) 20040101

Title: Nitrone-related therapeutics: potential of NXY-059 for the treatment of acute ischaemic stroke.

Journal: CNS drugs 20040101

Title: Protecting the brain: the search for a clinically effective neuroprotective drug for stroke.

Journal: Critical reviews in neurobiology 20040101

Title: Nitrones as neuroprotective agents in cerebral ischemia, with particular reference to NXY-059.

Journal: Pharmacology & therapeutics 20031201

Title: NXY-059, a nitrone with free radical trapping properties inhibits release of cytochrome c after focal cerebral ischemia.

Journal: Cellular and molecular biology (Noisy-le-Grand, France) 20031201

Title: Functional and histological evidence for the protective effect of NXY-059 in a primate model of stroke when given 4 hours after occlusion.

Journal: Stroke 20030901

Title: Comparison of the neuroprotective effect of clomethiazole, AR-R15896AR and NXY-059 in a primate model of stroke using histological and behavioural measures.

Journal: Brain research 20030516

Title: Tolerability of NXY-059 at higher target concentrations in patients with acute stroke.

Journal: Stroke 20030201

Title: Assessment of cognitive and motor deficits in a marmoset model of stroke.

Journal: ILAR journal 20030101

Title: NXY 059: CPI 22, NXY 059G.

Journal: Drugs in R&D 20030101

Title: Development of the nitrone-based spin trap agent NXY-059 to treat acute ischemic stroke.

Journal: CNS drug reviews 20030101

Title: NXY-059. Centaur.

Journal: Current opinion in investigational drugs (London, England : 2000) 20021201

Title: In vitro blood-brain barrier permeability and cerebral endothelial cell uptake of the neuroprotective nitrone compound NXY-059 in normoxic, hypoxic and ischemic conditions.

Journal: Brain research 20021115

Title: Pharmacokinetics in renally impaired subjects of NXY-059, a nitrone-based, free-radical trapping agent developed for the treatment of acute stroke.

Journal: European journal of clinical pharmacology 20020901

Title: NXY-059 maintains Akt activation and inhibits release of cytochrome C after focal cerebral ischemia.

Journal: Brain research 20020830

Title: Effects of the spin trap agent disodium- [tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (generic NXY-059) on intracerebral hemorrhage in a rabbit Large clot embolic stroke model: combination studies with tissue plasminogen activator.

Journal: Stroke 20020601

Title: Neuroprotective effects of the spin trap agent disodium-[(tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (generic NXY-059) in a rabbit small clot embolic stroke model: combination studies with the thrombolytic tissue plasminogen activator.

Journal: Stroke 20020501

Title: Effect of NXY-059 on secondary mitochondrial dysfunction after transient focal ischemia; comparison with cyclosporin A.

Journal: Brain research 20020405

Title: Effect of NXY-059 on infarct volume after transient or permanent middle cerebral artery occlusion in the rat; studies on dose, plasma concentration and therapeutic time window.

Journal: British journal of pharmacology 20020101

Title: NXY-059, a novel free radical trapping compound, reduces cortical infarction after permanent focal cerebral ischemia in the rat.

Journal: Brain research 20010803

Title: Comparison of the radical trapping ability of PBN, S-PPBN and NXY-059.

Journal: Free radical research 20010401

Title: Efficacy of disodium 4-[(tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (NXY-059), a free radical trapping agent, in a rat model of hemorrhagic stroke.

Journal: Neuropharmacology 20010301

Title: Tolerability and pharmacokinetics of the nitrone NXY-059 in patients with acute stroke.

Journal: Stroke 20010301

Title: NXY-059, a free radical--trapping agent, substantially lessens the functional disability resulting from cerebral ischemia in a primate species.

Journal: Stroke 20010101

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Related Products of 168021-79-2
Tags:168021-79-2 Molecular Formula|168021-79-2 MDL|168021-79-2 SMILES|168021-79-2 Cerovive